Edition:
United Kingdom

Repros Therapeutics Inc (RPRX.OQ)

RPRX.OQ on NASDAQ Stock Exchange Capital Market

0.66USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
215,523
52-wk High
$1.55
52-wk Low
$0.26

Chart for

About

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally... (more)
No analyst recommendations are available for .

Overall

Beta: 0.40
Market Cap(Mil.): $19.94
Shares Outstanding(Mil.): 37.62
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Repros Therapeutics Announces Acquisition By Allergan

* REPROS THERAPEUTICS INC.® ANNOUNCES ACQUISITION BY ALLERGAN PLC

12 Dec 2017

BRIEF-Repros Therapeutics Q3 loss per share $0.04

* Repros Therapeutics Inc.® reports third quarter 2017 financial results

13 Nov 2017

BRIEF-Rosalind Advisors reports 5.7 pct stake in Repros Therapeutics

* Rosalind Advisors Inc reports 5.7 percent passive stake in Repros Therapeutics Inc as of July 20 - SEC filing Source text: (http://bit.ly/2gXOAhU) Further company coverage:

24 Jul 2017

BRIEF-Repros Therapeutics ‍expects to receive European patent ‍​

* Repros Therapeutics Inc - ‍expects to receive European patent that relates to selective progesterone modulators​

17 Jul 2017

Earnings vs. Estimates